{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-112034","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.390135+00:00","generated_at":"2026-05-30T09:20:07.550254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M","bullets":["ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.","Net loss narrowed to $12.7M from $13.9M; cash $223.8M, no debt.","Over 2,550 prescribers since launch; average therapy duration ~27 months.","Phase 2b trial of abiprubart in Sjögren's Disease enrolling/dosing; expects annual cash flow positivity.","Launched Life DisRPted campaign with Henrik Lundqvist and Carly Pearce."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-112034","json":"https://secwatch.observer/filing/0001104659-24-112034.json","markdown":"https://secwatch.observer/filing/0001104659-24-112034.md","text":"https://secwatch.observer/filing/0001104659-24-112034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924112034/0001104659-24-112034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924112034/tm2426983d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:20:07.550254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}